Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Combination chemotherapy in vitro with cis-dichlorodiammineplatinum(II).

Literature DB >> 1021234

Combination chemotherapy in vitro with cis-dichlorodiammineplatinum(II).

Abstract

Cis-dichlorodiammineplatinum(II) (DDP) was paired with 11 other chemotherapeutic drugs in a search for possible synergistic pairs. Cell lethality was investigated by the colony-formation technique utilizing a long-term culture of human lymphoma cells. Synergistic effects were noted for pair combinations with all alkylating agents, bleomycin, adriamycin, camptothecin, and cytosine arabinoside. Additive effects were recorded for combinations with prednisolone and VP-16-213, while DDP reduced the capacity of cells to absorb sublethal damage induced by alkylating agents.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 1976 PMID： 1021234

Source DB: PubMed Journal: Cancer Treat Rep ISSN： 0361-5960

Keyword Cloud
Cited

16 in total

1. Modulation of antitumor alkylating agents by novobiocin, topotecan, and lonidamine.

Authors: G N Schwartz; B A Teicher; J P Eder; T Korbut; S A Holden; G Ara; T S Herman
Journal: Cancer Chemother Pharmacol Date: 1993 Impact factor: 3.333

2. Proliferative activity following induction chemotherapy in squamous cell carcinoma of the head and neck. A histopathological and immunohistochemical study using monoclonal antibodies.

Authors: R Bettinger; M Loerz; E Meyer-Breiting
Journal: Eur Arch Otorhinolaryngol Date: 1991 Impact factor: 2.503

3. Cytotoxic effects of topotecan combined with various active G2/M-phase anticancer drugs in human tumor-derived cell lines.

Authors: M Taron; C Plasencia; A Abad; C Martin; M Guillot
Journal: Invest New Drugs Date: 2000-05 Impact factor: 3.850

4. A phase II study of nimustine hydrochloride, cisplatin, and etoposide combination chemotherapy for supratentorial malignant gliomas.

Authors: T Beppu; Y Yoshida; H Arai; T Wada; M Suzuki; A Ogawa; S Hakozaki; N Kubo
Journal: J Neurooncol Date: 2000-09 Impact factor: 4.130

Review 5. Current development of podophyllotoxins.

Authors: R Canetta; P Hilgard; S Florentine; P Bedogni; L Lenaz
Journal: Cancer Chemother Pharmacol Date: 1982 Impact factor: 3.333

6. Addition of a topoisomerase I inhibitor to trimodality therapy [cis-diamminedichloroplatinum(II)/heat/radiation] in a murine tumor.

Authors: B A Teicher; S A Holden; V Khandakar; T S Herman
Journal: J Cancer Res Clin Oncol Date: 1993 Impact factor: 4.553

Combination chemotherapy in vitro with cis-dichlorodiammineplatinum(II).

1. Modulation of antitumor alkylating agents by novobiocin, topotecan, and lonidamine.

2. Proliferative activity following induction chemotherapy in squamous cell carcinoma of the head and neck. A histopathological and immunohistochemical study using monoclonal antibodies.

3. Cytotoxic effects of topotecan combined with various active G2/M-phase anticancer drugs in human tumor-derived cell lines.

4. A phase II study of nimustine hydrochloride, cisplatin, and etoposide combination chemotherapy for supratentorial malignant gliomas.

Review 5. Current development of podophyllotoxins.

6. Addition of a topoisomerase I inhibitor to trimodality therapy [cis-diamminedichloroplatinum(II)/heat/radiation] in a murine tumor.

7. In vitro chemosensitivity testing of Fotemustine (S 10036), a new antitumor nitrosourea.

Review 8. Intracavitary chemotherapy for malignant disease confined to body cavities.

9. [Etoposide VP 16--213)--a podophyllotoxinderivative with high antitumor activity (author's transl)].

10. Intraarterial cisplatin plus intravenous doxorubicin for inoperable recurrent meningiomas.